BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agin-Liebes G, Haas TF, Lancelotta R, Uthaug MV, Ramaekers JG, Davis AK. Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. ACS Pharmacol Transl Sci 2021;4:543-52. [PMID: 33860184 DOI: 10.1021/acsptsci.1c00018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Nikolaidis A, Lancelotta R, Gukasyan N, Griffiths RR, Barrett FS, Davis AK. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. J Affect Disord 2023;324:239-49. [PMID: 36584715 DOI: 10.1016/j.jad.2022.12.042] [Reference Citation Analysis]
2 Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Int J Mol Sci 2023;24. [PMID: 36674849 DOI: 10.3390/ijms24021329] [Reference Citation Analysis]
3 Vamvakopoulou IA, Narine KAD, Campbell I, Dyck JRB, Nutt DJ. Mescaline: The forgotten psychedelic. Neuropharmacology 2023;222:109294. [PMID: 36252614 DOI: 10.1016/j.neuropharm.2022.109294] [Reference Citation Analysis]
4 Bohn A, Kiggen MHH, Uthaug MV, van Oorsouw KIM, Ramaekers JG, van Schie HT. Altered States of Consciousness During Ceremonial San Pedro Use. The International Journal for the Psychology of Religion 2022. [DOI: 10.1080/10508619.2022.2139502] [Reference Citation Analysis]
5 Calleja-Conde J, Morales-García JA, Echeverry-Alzate V, Bühler KM, Giné E, López-Moreno JA. Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies. Addict Biol 2022;27:e13229. [PMID: 36301215 DOI: 10.1111/adb.13229] [Reference Citation Analysis]
6 Dourron HM, Strauss C, Hendricks PS, Barker E. Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis. Pharmacol Rev 2022;74:982-1027. [DOI: 10.1124/pharmrev.121.000514] [Reference Citation Analysis]
7 Kałużna A, Schlosser M, Gulliksen Craste E, Stroud J, Cooke J. Being no one, being One: The role of ego-dissolution and connectedness in the therapeutic effects of psychedelic experience. JPS 2022;6:111-136. [DOI: 10.1556/2054.2022.00199] [Reference Citation Analysis]
8 Bender E. Finding medical value in mescaline. Nature 2022;609:S90-1. [PMID: 36171368 DOI: 10.1038/d41586-022-02873-8] [Reference Citation Analysis]
9 Mendes FR, Costa CDS, Wiltenburg VD, Morales-lima G, Fernandes JAB, Filev R. Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research. Addiction Neuroscience 2022;3:100025. [DOI: 10.1016/j.addicn.2022.100025] [Reference Citation Analysis]
10 Schmitz GP, Jain MK, Slocum ST, Roth BL. 5-HT(2A) SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics. ACS Chem Neurosci 2022;13:2386-98. [PMID: 35894503 DOI: 10.1021/acschemneuro.1c00815] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
11 Nygart VA, Pommerencke LM, Haijen E, Kettner H, Kaelen M, Mortensen EL, Nutt DJ, Carhart-Harris RL, Erritzoe D. Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample. J Psychopharmacol 2022;36:932-42. [PMID: 35924888 DOI: 10.1177/02698811221101061] [Reference Citation Analysis]
12 Bhatt SR, Armstrong M, Parker T, Maviglia M, Kass R, Leeman L, Romo P, Ziedonis D. Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico. Front Pharmacol 2022;13:905753. [DOI: 10.3389/fphar.2022.905753] [Reference Citation Analysis]
13 Jones G, Lipson J, Nock MK. Associations between classic psychedelics and nicotine dependence in a nationally representative sample. Sci Rep 2022;12:10578. [PMID: 35732796 DOI: 10.1038/s41598-022-14809-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gandy S. Predictors and potentiators of psychedelic-occasioned mystical experiences. JPS 2022. [DOI: 10.1556/2054.2022.00198] [Reference Citation Analysis]
15 Jones GM, Nock MK. Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study. Sci Rep 2022;12:2574. [PMID: 35173246 DOI: 10.1038/s41598-022-06580-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ. Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. J Psychopharmacol 2022;:2698811211069100. [PMID: 35107059 DOI: 10.1177/02698811211069100] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
17 Earleywine M, Low F, De Leo J. A Semantic Scale Network analysis of the revised Mystical Experiences Questionnaire: A call for collaboration. JPS 2022;5:156-65. [DOI: 10.1556/2054.2021.00187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lee YK, Gold MS, Fuehrlein BS. Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder. J Neurol Sci 2022;432:120094. [PMID: 34933249 DOI: 10.1016/j.jns.2021.120094] [Reference Citation Analysis]
19 Khan AJ, Bradley E, O’donovan A, Woolley J. Psilocybin for Trauma-Related Disorders. Disruptive Psychopharmacology 2022. [DOI: 10.1007/7854_2022_366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Schmitz GP, Jain MK, Slocum ST, Roth BL. Pharmacologic analysis of non-synonymous coding 5-HT2A SNPs reveals alterations psychedelic drug potencies and efficacies.. [DOI: 10.1101/2021.12.09.472000] [Reference Citation Analysis]
21 Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW, Hendricks PS. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. Int J Drug Policy 2021;98:103380. [PMID: 34329952 DOI: 10.1016/j.drugpo.2021.103380] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]